Fax completed form to: (833) 470-1448
infusion solutions

| PATIENT INFORMATION |  |  |
| :---: | :---: | :---: |
| Patient Name: $\quad$ Date of Birth: |  | Referral Date: |
| Address: |  | City/State/Zip: |
| Home Phone: $\quad$ Cell Phone: | Cell Phone: | WorkPhone: |
| Secondary Contact: $\quad$ Height: | Weight: | $\square$ Male $\square$ Female |
| Patient Diagnosis \& ICD-10: |  |  |
| Allergies: |  |  |
| PROVIDER INFORMATION |  |  |
| Physician Name: $\quad$ Lic.\#: | Lic.\#: | DEA \#: |
| Practice Name: |  | NPI\#: |
| Address: |  | City/State/Zip: |
| Office Contact: $\quad$ Phone: | Phone: | Fax: |
| Supervisory Physician (if applicable): |  |  |
| PLEASE ATTACH |  |  |
| Patient demographics \& front/back copy of all insurance cards (prescription \& medical) Recent office visit notes, history \& physial, lab \& pertinent procedure results Current medication list \& list of prior medications tried and failed (with dates) Line access documentation/verification if applicable Quantitative serum Immunoglobulin lab results (Uplizna only) TB lab results within last 12 months (Uplizna only) | $\square$ Vaccine $\square$ HBV lab $\square$ Date of $\square$ Anti-act $\square$ Letter of | nation) and documentation of any recent vaccinations <br> t 12 months (Uplizna only) <br> FVC\%, ALSFRS-R score, and JourneyMate form (Radicava only) <br> or (AChR) antibody positive results (Vyvgart) <br> ty if drug dosing or indication is outside of FDA guidelines |

## NURSING \& LAB ORDERS

Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.
Flush Orders: NaC10.9\%-5-10mL flush pre and post infusion and as needed Heparin - $\square 10$ units/mL $---0 R-\square 100$ units $/ \mathrm{mL}-3-5 \mathrm{~mL}$ flush after post-infusion NS flush ifindicated to maintain line Lab Orders:

Lab Date \& Frequency:


Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary

## PRODUCT

## PRESCRIPTION INFORMATION

|  | Is this a first dose? $\square$ Yes $\square$ No If N 0 , when was last dose given? ___ When is patient due for next dose? |  |
| :---: | :---: | :---: |
|  | $\square$ Induction: 60 mg IV infusion via $\square$ gravity ---OR--- $\square$ pump over 1 hour daily for 14 days followed by 14 day drug-free period | NONE |
| - radicava | $\square$ Maintenance: 60 mg IV infusion via $\square$ gravity ---0R-- $\square$ pump over 1 hour daily for 10 days out of 14 day period followed by 14 day drug-free periods |  |
| $\square$ UPLIZNA | $\square$ Induction: 300 mg IV infusion via $\square$ gravity -- -OR-- $\square$ pump over approximately 90 minutes at 0 and 2 weeks and CBClab testing every ___ months | NONE |
|  | $\square$ Maintenance: (starting 6 months from firstinfusion) 300 mg IV infusion via $\square$ gravity ---OR-- $\square$ pump over approximately 90 minutes every 6 months |  |
| $\square$ VYEPTI | $\begin{aligned} & \square 100 \mathrm{mg} \text { IV infusion via } \square \text { gravity ---OR--- } \square \text { pump over approximately } 30 \text { minutes every } 12 \text { weeks } \\ & \square 300 \mathrm{mg} \text { IV infusion via } \square \text { gravity ---OR--- } \square \text { pump over approximately } 30 \text { minutes every } 12 \text { weeks } \end{aligned}$ |  |
| $\square$ VYVGART | $10 \mathrm{mg} / \mathrm{kg}$ IV infusion via $\square$ gravity ---OR--- --OR--- pump over at least 1 hour once every week for 4 weeks *Up to max of 1200 mg for patient weight of $120 \mathrm{~kg}+$ (Total volume is 125 ml in NS solution) <br> Administer additional treatment cycles $\square$ every 50 days ---OR-- $\square$ Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established. |  |
| $\square$ VYVGART HYTRULO | $1,008 \mathrm{mg} / 11,200$ units subcutaneous injection over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks Administer additional treatment cycles $\square$ every 50 days -- OR--- $\square$ Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established. |  |
| $\square \mathrm{IG}$ | Referto Immunoglobulin Form |  |
| $\square$ SOLRIS/ULTOMRIS | Referto Soliris or Ultomiris Order Form |  |
| $\square$ OTHER |  | NONE |
| By signing this form and utilizing our services, you are authorizing Mosaic to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies. |  |  |

## Prescriber's Signature <br> Dispense as Written

Print Name
Date
mosaiciv.com
©2023 Amerita Inc. All rights reserved.
MOS OO Neuro ORDER FORM 08-14-23

Prescriber's Signature Substitution Permitted

Print Name

Date

